NRK Inhibitors
NRK inhibitors encompass a variety of chemical compounds that indirectly impinge upon the kinase's functional activity by targeting specific signaling pathways and biological processes. For instance, some inhibitors primarily target upstream kinases that are pivotal for NRK activation; by mitigating the phosphorylation cascade, these inhibitors effectively reduce NRK activity. Others exert their inhibitory effect by modulating key pathways such as the MAPK, PI3K, and mTOR pathways, which are crucial for the regulation and activation of a wide array of kinases including NRK. Kinase inhibitors like those that inhibit p38 MAP kinase or PKC isoforms serve to dampen the kinase signaling cascades and thereby attenuate NRK activation. Moreover, certain inhibitors disrupt the machinery of cell cycle regulation, potentially affecting the activation state and function of NRK due to its involvement in cellular proliferation and growth processes.
The biochemical inhibition mechanisms of NRK, therefore, are multifaceted, with each inhibitor exerting its influence through distinct yet converging pathways. Inhibitors that target the JNK pathway, for example, reduce the phosphorylation signals that contribute to the activation of NRK, while inhibitors of the Src family kinases decrease the kinase's activation through a different route. Additionally, compounds that are potent inhibitors of receptor tyrosine kinases may also diminish NRK's activity by virtue of their effect on the broader signaling landscape of which NRK is a part. The intricate interplay of these pathways, all of which converge upon NRK, underscores the complexity of modulating kinase activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that affects a wide range of kinases. By inhibiting upstream kinases that activate NRK, this compound indirectly reduces NRK's kinase activity. | ||||||
PP 1 | 172889-26-8 | sc-203212 sc-203212A | 1 mg 5 mg | $84.00 $142.00 | 6 | |
A selective inhibitor of Src family kinases. As Src kinases can phosphorylate and activate other kinases, PP 1 can indirectly diminish the phosphorylation activity of NRK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP 600125 may reduce the phosphorylation signals that could contribute to NRK activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A selective inhibitor of mitogen-activated protein kinase kinase (MEK). PD 98059 indirectly inhibits NRK by blocking MEK, which may participate in activating NRK through the MAPK pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A pyridinyl imidazole compound that specifically inhibits p38 MAP kinase. By inhibiting p38 MAP kinase, SB 203580 could reduce the kinase signaling cascades that involve NRK activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A morpholine derivative and a potent inhibitor of phosphoinositide 3-kinases (PI3K). By attenuating PI3K signaling, LY 294002 may lead to reduced activation of kinases, including NRK. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can indirectly inhibit protein kinases like NRK by disrupting mTOR signaling pathways, which are upstream of several kinase cascades. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
A potent inhibitor of protein kinase C (PKC) isoforms. Inhibition of PKC can lead to decreased activation of kinases downstream or within the same pathway as NRK. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A potent and irreversible inhibitor of PI3K. By inhibiting the PI3K pathway, Wortmannin can lead to a decrease in NRK signaling and activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
A multi-targeted kinase inhibitor that, among other kinases, can inhibit Src family kinases. By doing so, Dasatinib can indirectly decrease the phosphorylation and activation of NRK. | ||||||